To STRIDE or not to STRIDE: a critique of “treat to target” in Crohn´s disease

References

• Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–530. doi: 10.1053/gast.2002.31072
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology. 1979;77:843–846. doi: 10.1016/0016-5085(79)90384-6
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629. doi: 10.1056/NEJM198712243172603
   PubMed Web of Science ®Google Scholar
• Pariente B, Mary J-Y, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52–63.e3. doi: 10.1053/j.gastro.2014.09.015
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi: 10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789. doi: 10.1016/S0140-6736(17)32641-7
   PubMed Web of Science ®Google Scholar
• Laharie D, D’Haens G, Nachury M, et al. Steroid-free deep remission at one year does not prevent Crohn’s disease progression: long-term data from the TAILORIX trial. Clin Gastroenterol Hepatol. 2022;20(9):2074–2082. doi: 10.1016/j.cgh.2021.11.030
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, D’Haens G, et al. Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7(4):294–306. doi: 10.1016/S2468-1253(21)00474-X
   PubMed Web of Science ®Google Scholar
• Yang JY, Lund JL, Funk MJ, et al. Utilization of treat-to-target monitoring colonoscopy after treatment initiation in the US-Based study of a prospective adult research cohort with inflammatory bowel disease. Am J Gastroenterol. 2023;118(9):1638–1647. doi: 10.14309/ajg.0000000000002294
   PubMed Web of Science ®Google Scholar
• Garcia NM, Cohen NA, Rubin DT. Treat-to-target and sequencing therapies in Crohn’s disease. United Eur Gastroenterol J. 2022;10(10):1121–1128. doi: 10.1002/ueg2.12336
   PubMed Web of Science ®Google Scholar
• Queiroz NSF, Cheifetz AS, Papamichael K. Going beyond a treat-to-target to a Treat-to-clear and a Treat-to-Trough therapeutic strategy in patients with inflammatory Bowel disease? J Crohns Colitis. 2023;17(6):825–826. doi: 10.1093/ecco-jcc/jjad014
   PubMed Web of Science ®Google Scholar
• Le Berre C, Peyrin-Biroulet L, Sandborn WJ. SPIRIT-IOIBD study group. Selecting end points for disease-modification trials in inflammatory Bowel disease: the SPIRIT consensus from the IOIBD. Gastroenterology. 2021;160(5):1452–1460.e21. doi: 10.1053/j.gastro.2020.10.065
   PubMed Web of Science ®Google Scholar
• Khanna R, Zou G, D’Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity. Aliment Pharmacol Ther. 2015;41(1):77–86. doi: 10.1111/apt.13001
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lewis JD, Panes J, et al. Association between proposed definitions of clinical remission/Response and well-being in patients with Crohn’s disease. J Crohns Colitis. 2022;16(3):444–451. doi: 10.1093/ecco-jcc/jjab161
   PubMed Web of Science ®Google Scholar
• Laterza L, Piscaglia AC, Minordi LM, et al. Multiparametric evaluation predicts different mid-term outcomes in Crohn’s disease. Dig Dis. 2018;36(3):184–193. doi: 10.1159/000487589
   PubMed Web of Science ®Google Scholar
• Lewis JD, Rutgeerts P, Feagan BG, et al. Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn’s disease. Inflamm Bowel Dis. 2020;26(2):304–313. doi: 10.1093/ibd/izz241
   PubMed Web of Science ®Google Scholar
• Tse CS, Singh S, Valasek MA, et al. Prevalence and correlations of gastrointestinal symptoms with endoscopic and histologic mucosal healing in Crohn’s disease. Am J Gastroenterol. 2023;118(4):748–751. doi: 10.14309/ajg.0000000000002122
   PubMed Web of Science ®Google Scholar
• Rajan A, Pan Y, Mahtani P, et al. The impact of confounders on symptom–endoscopic discordances in Crohn’s disease. Crohns Colitis. 2023;5(2):otad017. doi: 10.1093/crocol/otad017
   PubMedGoogle Scholar
• Hellmann J, Ta A, Ollberding NJ, et al. Patient-reported outcomes correlate with microbial community composition independent of mucosal inflammation in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2023;29(2):286–296. doi: 10.1093/ibd/izac175
   PubMed Web of Science ®Google Scholar
• Morris MW, Stewart SA, Heisler C, et al. Biomarker-based models outperform patient-reported scores in predicting endoscopic inflammatory disease activity. Inflamm Bowel Dis. 2018;24(2):277–285. doi: 10.1093/ibd/izx018
   PubMed Web of Science ®Google Scholar
• de Jong MJ, Roosen D, JHRJ D, et al. Development and validation of a patient-reported score to screen for mucosal inflammation in inflammatory bowel disease. J Crohns Colitis. 2019;13:555–563. doi: 10.1093/ecco-jcc/jjy196
   PubMed Web of Science ®Google Scholar
• Wong ECL, Dulai PS, Marshall JK, et al. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease. Aliment Pharmacol Ther. 2022;55(9):1151–1159. doi: 10.1111/apt.16805
   PubMed Web of Science ®Google Scholar
• Decker B, Tuzil J, Lukas M, et al. Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert Rev Gastroenterol Hepatol. 2023;17(1):99–108. doi: 10.1080/17474124.2023.2161047
   PubMed Web of Science ®Google Scholar
• Kamp KJ, Hawes SE, Tse CS, et al. Concordance and discordance between patient-reported remission, patient-reported outcomes, and physician global assessment. Inflamm Bowel Dis. 2023;29(8):1255–1262. doi: 10.1093/ibd/izac206
   PubMed Web of Science ®Google Scholar
• Varma A, Weinstein J, Seabury J, et al. Patient-reported impact of symptoms in Crohn’s disease. Am J Gastroenterol. 2022;117(12):2033–2045. doi: 10.14309/ajg.0000000000001954
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. The Lancet. 1980;315(8167):514. doi: 10.1016/S0140-6736(80)92767-1
   Google Scholar
• Wong D, Matini L, Kormilitzin A, et al. Patient-reported outcomes: the ICHOM standard set for inflammatory bowel disease in real-life practice helps quantify deficits in Current care. J Crohns Colitis. 2022;16(12):1874–1881. doi: 10.1093/ecco-jcc/jjac099
   PubMed Web of Science ®Google Scholar
• Schoefs E, Vermeire S, Ferrante M, et al. What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study. J Crohns Colitis. 2023;17(3):379–388. doi: 10.1093/ecco-jcc/jjac145
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on the development of new medicinal products for the treatment of Crohn’s disease. CPMP/EWP/2284/99 Rev. 2 [Internet]. European Medicines Agency; 2018. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-new-medicinal-products-treatment-crohns-disease-revision-2_en.pdf
   Google Scholar
• Janssen LM, Creemers RH, Van Bodegraven AA, et al. A systematic review on long-term efficacy outcome measures in Crohn’s disease patients. J Crohn’s & Colitis. 2023;17(9):1528–1536. doi: 10.1093/ecco-jcc/jjad037
   PubMed Web of Science ®Google Scholar
• Crohn’s disease: developing drugs for treatment guidance for industry [internet]. U.S. Department of Health and Human Services Food and Drug Administration; 2022. Available from: https://www.fda.gov/media/158001/download
   Google Scholar
• Horrigan JM, Louis E, Spinelli A, et al. The real-world global use of patient-reported outcomes for the care of patients with inflammatory bowel disease. Crohns Colitis. 2023;5(2):otad006. doi: 10.1093/crocol/otad006
   PubMedGoogle Scholar
• Collaborators C-I, Ma C, Hanzel J, et al. CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory Bowel disease. Gastroenterology. 2022;163:950–964. doi: 10.1053/j.gastro.2022.06.068
   PubMed Web of Science ®Google Scholar
• Falvey JD, Hoskin T, Meijer B, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21(4):824–831. doi: 10.1097/MIB.0000000000000341
   PubMed Web of Science ®Google Scholar
• Chen J-M, Liu T, Gao S, et al. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China. World J Gastroenterol. 2017;23(46):8235–8247. doi: 10.3748/wjg.v23.i46.8235
   PubMed Web of Science ®Google Scholar
• Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018;27(3):299–306. doi: 10.15403/jgld.2014.1121.273.pti
   PubMed Web of Science ®Google Scholar
• Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis. 2017;23(6):894–902. doi: 10.1097/MIB.0000000000001082
   PubMed Web of Science ®Google Scholar
• Haisma S-M, Verkade HJ, Scheenstra R, et al. Time-to-reach target calprotectin level in newly diagnosed patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;69(4):466–473. doi: 10.1097/MPG.0000000000002458
   PubMed Web of Science ®Google Scholar
• Plevris N, Fulforth J, Lyons M, et al. Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021;19(9):1835–1844.e6. doi: 10.1016/j.cgh.2020.08.022
   PubMed Web of Science ®Google Scholar
• Plebani M. Why C-reactive protein is one of the most requested tests in clinical laboratories? Clin Chem Lab Med. 2023;61(9):1540–1545. doi: 10.1515/cclm-2023-0086
   PubMed Web of Science ®Google Scholar
• Minderhoud IM, Steyerberg EW, van Bodegraven AA, et al. Predicting endoscopic disease activity in Crohn’s disease: a new and validated noninvasive disease activity index (the utrecht activity index). Inflamm Bowel Dis. 2015;21:2453–2459. doi: 10.1097/MIB.0000000000000507
   PubMed Web of Science ®Google Scholar
• Brand EC, Elias SG, Minderhoud IM, et al. Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn’s disease. Clin Gastroenterol Hepatol. 2020;18(8):1704–1718. doi: 10.1016/j.cgh.2019.12.014
   PubMed Web of Science ®Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–989. doi: 10.1136/gut.30.7.983
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512. doi: 10.1016/S0016-5107(04)01878-4
   PubMed Web of Science ®Google Scholar
• Bossuyt P, Louis E, Mary J-Y, et al. Defining endoscopic remission in Ileocolonic Crohn’s disease: let’s start from scratch. J Crohns Colitis. 2018;12(10):1245–1248. doi: 10.1093/ecco-jcc/jjy097
   PubMed Web of Science ®Google Scholar
• Khanna R, Ma C, Hogan M, et al. Standardizing scoring conventions for Crohn’s disease endoscopy: an international RAND/UCLA appropriateness study. Clin Gastroenterol Hepatol. 2023;21(11):2938–2950.e6. doi: 10.1016/j.cgh.2023.05.029
   PubMed Web of Science ®Google Scholar
• Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002;97:947–953. doi: 10.1016/S0002-9270(02)03970-9
   PubMed Web of Science ®Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–422. doi: 10.1053/j.gastro.2007.05.051
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–468; quiz e10–11. doi: 10.1053/j.gastro.2009.09.056
   Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in crohnʼs disease. Inflamm Bowel Dis. 2009;15(9):1295–1301. doi: 10.1002/ibd.20927
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn’s disease. Gastroenterology. 2020;159(1):139–147. doi: 10.1053/j.gastro.2020.03.039
   PubMed Web of Science ®Google Scholar
• Ferrante M, Colombel J-F, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145:978–986.e5. doi: 10.1053/j.gastro.2013.08.010
   PubMed Web of Science ®Google Scholar
• Magro F, Sabino J, Rosini F, et al. ECCO position on harmonisation of Crohn’s disease mucosal histopathology. J Crohn’s Colitis. 2022;16(6):876–883. doi: 10.1093/ecco-jcc/jjac006
   Google Scholar
• Magro F, Lopes J, Borralho P, et al. Comparing the continuous geboes score with the robarts histopathology index: definitions of histological remission and response and their relation to faecal calprotectin levels. J Crohns Colitis. 2020;14(2):169–175. doi: 10.1093/ecco-jcc/jjz123
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Picchio M, et al. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn’s disease patients in primary gastroenterology centres. Eur J Intern Med. 2014;25(5):485–490. doi: 10.1016/j.ejim.2014.02.010
   PubMed Web of Science ®Google Scholar
• Roseira J, Santiago M, Estevinho MM, et al. Impact of Crohn’s disease therapies on histology in randomized controlled trials: systematic review with meta-analysis. Inflamm Bowel Dis. 2023;29(8):1231–1243. doi: 10.1093/ibd/izac203
   PubMed Web of Science ®Google Scholar
• Rath T, Atreya R, Bodenschatz J, et al. Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in inflammatory bowel disease: the prospective ERIca Trial. Gastroenterology. 2023;164(2):241–255. doi: 10.1053/j.gastro.2022.10.014
   PubMed Web of Science ®Google Scholar
• Geyl S, Guillo L, Laurent V, et al. Transmural healing as a therapeutic goal in Crohn’s disease: a systematic review. Lancet Gastroenterol Hepatol. 2021;6(8):659–667. doi: 10.1016/S2468-1253(21)00096-0
   PubMed Web of Science ®Google Scholar
• Ordás I, Rimola J, Rodríguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology. 2014;146:374–382.e1. doi: 10.1053/j.gastro.2013.10.055
   PubMed Web of Science ®Google Scholar
• Zhu N-Y, Zhao X-S, Miao F. Magnetic resonance imaging and Crohn’s disease endoscopic index of severity: correlations and concordance. World J Gastroenterol. 2018;24(21):2279–2290. doi: 10.3748/wjg.v24.i21.2279
   PubMed Web of Science ®Google Scholar
• Deepak P, Fletcher JG, Fidler JL, et al. Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn’s disease. Am J Gastroenterol. 2016;111(7):997–1006. doi: 10.1038/ajg.2016.177
   PubMed Web of Science ®Google Scholar
• Fernandes SR, Rodrigues RV, Bernardo S, et al. Transmural healing is associated with improved long-term outcomes of patients with crohnʼs disease. Inflamm Bowel Dis. 2017;23(8):1403–1409. doi: 10.1097/MIB.0000000000001143
   PubMed Web of Science ®Google Scholar
• Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11:274–280. doi: 10.1093/ecco-jcc/jjw185
   PubMed Web of Science ®Google Scholar
• Takenaka K, Kawamoto A, Kitazume Y, et al. Transmural remission characterized by high biologic concentrations demonstrates better prognosis in Crohn’s disease. J Crohns Colitis. 2023;17(6):855–862. doi: 10.1093/ecco-jcc/jjac185
   PubMed Web of Science ®Google Scholar
• Mainenti PP, Castiglione F, Rispo A, et al. MR-enterography in Crohn’s disease: what MRE mural parameters are associated to one-year therapeutic management outcome? Br J Radiol. 2021;94(1118):20200844. doi: 10.1259/bjr.20200844
   PubMed Web of Science ®Google Scholar
• Hallé E, Azahaf M, Duveau N, et al. Radiological response is associated with better outcomes and should be considered a therapeutic target in Crohn’s disease. Dig Dis Sci. 2020;65(9):2664–2674. doi: 10.1007/s10620-019-05979-8
   PubMed Web of Science ®Google Scholar
• Novak KL, Kaplan GG, Panaccione R, et al. A simple ultrasound score for the accurate detection of inflammatory activity in crohnʼs disease. Inflamm Bowel Dis. 2017;23(11):2001–2010. doi: 10.1097/MIB.0000000000001174
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kunisaki R, Kinoshita H, et al. Use of color doppler ultrasonography for evaluating vascularity of small intestinal lesions in Crohn’s disease: correlation with endoscopic and surgical macroscopic findings. Scand J Gastroenterol. 2014;49(3):295–301. doi: 10.3109/00365521.2013.871744
   PubMed Web of Science ®Google Scholar
• Ripollés T, Paredes JM, Martínez-Pérez MJ, et al. Ultrasonographic changes at 12 weeks of anti-TNF drugs predict 1-year sonographic response and clinical outcome in crohnʼs disease. Inflamm Bowel Dis. 2016;22(10):2465–2473. doi: 10.1097/MIB.0000000000000882
   PubMed Web of Science ®Google Scholar
• Kucharzik T, Wilkens R, D’Agostino M-A, et al. Early ultrasound response and progressive transmural remission after treatment with ustekinumab in Crohn’s disease. Clin Gastroenterol Hepatol. 2023;21(1):153–163.e12. doi: 10.1016/j.cgh.2022.05.055
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–769. doi: 10.1016/S0016-5085(99)70332-X
   PubMed Web of Science ®Google Scholar
• Feagan B, Sandborn WJ, Rutgeerts P, et al. Performance of Crohn’s disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: analysis of EXTEND data. Inflamm Bowel Dis. 2018;24(5):932–942. doi: 10.1093/ibd/izx082
   PubMed Web of Science ®Google Scholar
• Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–2211. doi: 10.1016/S0140-6736(22)00688-2
   PubMed Web of Science ®Google Scholar
• D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–2030. doi: 10.1016/S0140-6736(22)00467-6
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650–1664.e8. doi: 10.1053/j.gastro.2022.01.047
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Stange EF. Twenty-five years of biologicals in IBD: what´s all the hype about? J Intern Med. 2021;290(4):806–825. doi: 10.1111/joim.13345
   PubMed Web of Science ®Google Scholar
• Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–1980. doi: 10.1056/NEJMoa2212728
   PubMed Web of Science ®Google Scholar
• Kayal M, Ungaro RC, Bader G, et al. Net remission rates with biologic treatment in Crohn’s disease: a reappraisal of the clinical trial data. Clin Gastroenterol Hepatol. 2023;21(5):1348–1350. doi: 10.1016/j.cgh.2022.02.044
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064. doi: 10.1007/s00535-018-1480-0
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Gilmore R, van Langenberg D, et al. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease. Therap Adv Gastroenterol. 2022;15:17562848211070940. doi: 10.1177/17562848211070940
   Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353. doi: 10.1016/S2468-1253(19)30012-3
   PubMed Web of Science ®Google Scholar
• Panaccione R, Lee W-J, Clark R, et al. Dose escalation patterns of advanced therapies in Crohn’s disease and ulcerative colitis: a systematic literature review. Adv Ther. 2023;40(5):2051–2081. doi: 10.1007/s12325-023-02457-6
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti–tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333. doi: 10.1053/j.gastro.2005.11.030
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337(15):1029–1036. doi: 10.1056/NEJM199710093371502
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. doi: 10.1056/NEJMoa1602773
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721. doi: 10.1056/NEJMoa1215739
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of Upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123–2138.e8. doi: 10.1053/j.gastro.2020.01.047
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, Azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395. doi: 10.1056/NEJMoa0904492
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41(8):734–746. doi: 10.1111/apt.13139
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102–1111.e2. doi: 10.1053/j.gastro.2012.01.035
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–838. doi: 10.7326/0003-4819-146-12-200706190-00159
   PubMed Web of Science ®Google Scholar
• Danese S, Sandborn WJ, Colombel J-F, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology. 2019;157(4):1007–1018.e7. doi: 10.1053/j.gastro.2019.06.038
   PubMed Web of Science ®Google Scholar
• Löwenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s disease. Gastroenterology. 2019;157(4):997–1006.e6. doi: 10.1053/j.gastro.2019.05.067
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate–severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–1155. doi: 10.1038/ajg.2016.236
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Gasink C, Chan D, et al. Efficacy of Ustekinumab for inducing endoscopic healing in patients with Crohn’s disease. Gastroenterology. 2018;155(4):1045–1058. doi: 10.1053/j.gastro.2018.06.035
   PubMed Web of Science ®Google Scholar
• Plevris N, Fulforth J, Siakavellas S, et al. Real‐world effectiveness and safety of ustekinumab for the treatment of Crohn’s disease: the Scottish ustekinumab cohort. J Gastro Hepatol. 2021;36(8):2067–2075. doi: 10.1111/jgh.15390
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Sandborn WJ, Loftus EV, et al. Higher vs Standard Adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results. Gastroenterology. 2022;162(7):1876–1890. doi: 10.1053/j.gastro.2022.01.044
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Schultheiss H-P, Louwers J, et al. Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022;20(11):2577–2587.e6. doi: 10.1016/j.cgh.2022.01.019
   PubMed Web of Science ®Google Scholar
• Sturm A, Atreya R, Bettenworth D, et al. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“der Deutschen Gesellschaft fur Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol. 2022;60:332–418. doi: 10.1055/a-1713-3941
   PubMedGoogle Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi: 10.1136/gutjnl-2019-318484
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohn’s Colitis. 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180
   Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. doi: 10.1038/ajg.2018.27
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and Perianal Fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2496–2508. doi: 10.1053/j.gastro.2021.04.022
   PubMed Web of Science ®Google Scholar
• Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015;148(1):37–51.e1. doi: 10.1053/j.gastro.2014.08.003
   PubMed Web of Science ®Google Scholar
• Alsoud D, Verstockt B, Fiocchi C, et al. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589–595. doi: 10.1016/S2468-1253(21)00065-0
   PubMed Web of Science ®Google Scholar
• Stange EF, Schroeder BO. Microbiota and mucosal defense in IBD: an update. Expert Rev Gastroenterol Hepatol. 2019;13(10):963–976. doi: 10.1080/17474124.2019.1671822
   PubMed Web of Science ®Google Scholar
• Ilvemark JFKF, Hansen T, Goodsall TM, et al. Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement. J Crohns Colitis. 2022;16(4):554–580. doi: 10.1093/ecco-jcc/jjab173
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Stange EF. Prioritization in inflammatory bowel disease therapy. Expert Rev Gastroenterol Hepatol. 2023;17(8):753–767. doi: 10.1080/17474124.2023.2240699
   PubMed Web of Science ®Google Scholar
• Maaser C, Petersen F, Helwig U, et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut. 2020;69(9):1629–1636. doi: 10.1136/gutjnl-2019-319451
   PubMed Web of Science ®Google Scholar